Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea
IXHL•Phase 2 DReAMzz screening begins
Incannex began screening participants in its DReAMzz Phase 2 dose-confirmation trial of IHL-42X for obstructive sleep apnea.
First sites are screening now; additional sites are expected to start as approvals are secured.
Prior Phase 2 data and development path
Incannex cited prior Phase 2 results showing up to 83% reduction in apnea-hypopnea index, with improvements in patient-reported outcomes.
IHL-42X holds FDA Fast Track designation, supporting a potentially expedited regulatory path ahead of planned Phase III development.
